{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T11:31:40Z","timestamp":1695209500340},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jhep.2016.06.014","type":"journal-article","created":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T16:17:12Z","timestamp":1471277832000},"page":"465-466","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Myrcludex B, a novel therapy for chronic hepatitis D?"],"prefix":"10.1016","volume":"65","author":[{"given":"Mario","family":"Rizzetto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia Anna","family":"Niro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.06.014_b0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2893.2005.00601.x","article-title":"Treatment of hepatitis D","volume":"12","author":"Niro","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.06.014_b0010","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/hep.27585","article-title":"Pegylated interferon therapy of chronic hepatitis D: in need of revision","volume":"61","author":"Rizzetto","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.06.014_b0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0032-1323623","article-title":"Virology of hepatitis D virus","volume":"32","author":"Taylor","year":"2012","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2016.06.014_b0020","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.06.014_b0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.06.014_b0030","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.06.014_b0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2014.03.002","article-title":"Mouse models of hepatitis B and delta virus infection","volume":"410","author":"Dandri","year":"2014","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jhep.2016.06.014_b0040","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.24758","article-title":"Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation","volume":"55","author":"Lutgehetmann","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.06.014_b0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12788","article-title":"Long-term therapy of chronic delta hepatitis with peginterferon alfa","volume":"40","author":"Heller","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.06.014_b0050","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jhep.2012.12.019","article-title":"Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta","volume":"58","author":"Ouzan","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.06.014_b0055","doi-asserted-by":"crossref","unstructured":"Niro GA, Smedile A, Fontana R, Olivero A, Ciancio A, Valvano, M, et al. HBsAg kinetics in chronic hepatitis D during interferon therapy. On-treatment prediction of response. Aliment Pharmacol Ther; in press.","DOI":"10.1111\/apt.13734"},{"key":"10.1016\/j.jhep.2016.06.014_b0060","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1365-2036.2012.04993.x","article-title":"Meta-analysis: antiviral treatment for hepatitis D","volume":"35","author":"Triantos","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.06.014_b0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.06.014_b0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/infdis\/155.1.72","article-title":"Titration of the infectivity of hepatitis D virus in chimpanzees","volume":"155","author":"Ponzetto","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2016.06.014_b0075","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1055\/s-0032-1323627","article-title":"Hepatitis delta virus diagnosis","volume":"32","author":"Olivero","year":"2012","journal-title":"Semin Liver Dis"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816302768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816302768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T06:25:02Z","timestamp":1536474302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816302768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0168827816302768"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.06.014","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myrcludex B, a novel therapy for chronic hepatitis D?","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.04.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.04.016","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}